| Literature DB >> 35719442 |
Kulbeer Kaur1, Kajal Jain2, Manisha Biswal3, Surinder Kaur Dayal4.
Abstract
Introduction: The Centres for Disease Control and Prevention (CDC) introduced a new definition of ventilator-associated events (VAEs) in 2013 in place of longstanding ventilator-associated pneumonia (VAP) definition. Three entities under VAE, ventilator-associated condition (VAC), infection-related ventilator-associated complication (IVAC), and possible ventilator-associated pneumonia (PVAP), were introduced.Entities:
Keywords: Infection-related ventilator-associated complication; Possible ventilator-associated pneumonia; Ventilator-associated condition; Ventilator-associated events; Ventilator-associated pneumonia
Year: 2022 PMID: 35719442 PMCID: PMC9160630 DOI: 10.5005/jp-journals-10071-24157
Source DB: PubMed Journal: Indian J Crit Care Med ISSN: 0972-5229
Flowchart 1Ventilator-associated events (VAE) surveillance algorithm
VAP_ PNEU1 criteria (CDC)
| For ANY PATIENT, at least Fever (>38.0°C or >100.4°F) Leukopenia (≤4,000 WBC/mm3) or leukocytosis (>12,000 WBC/mm3) For adults >70 years old, altered mental status with no other recognized cause |
| And at least New onset of purulent sputum or change in character of sputum, or increased respiratory secretions, or increased suctioning requirements New onset or worsening cough, or dyspnea, or tachypnea Rales or bronchial breath sounds Worsening gas exchange (for example: O2 desaturations (for example: PaO2/FiO2 <240), increased oxygen requirements, or increased ventilator demand) |
| Two or more serial chest imaging test results with at least one of the following: |
| New and persistent |
| or |
| Progressive and persistent
Infiltrate Consolidation Cavitation Pneumatoceles, in infants ≤1-year-old |
Demographic data of study participants
|
|
| |
|---|---|---|
| Admission units | Neurosurgery | 264 (69.8) |
| Gender | Male | 288 (76.2) |
| Age (years) | <18 | 84 (22.2) |
| Previous unit | Emergency | 277 (73.3) |
| Intubation | Before ICU admission | 189 (50) |
| End status | Expired | 81 (21.4) |
| Trauma with head injury | Yes | 231(61.1) |
| Comorbidity** | Present | 27 (7.1) |
*Left against medical advice
**Diabetes mellitus, hypertension, asthma, alcoholism, coronary artery disease, hypothyroidism, and cerebrovascular accident
Incidence of VAP and VAE in trauma ICU from July 2018 till June 2019
|
|
|
|
|---|---|---|
| VAP | 28 (7.41) | 9.24 |
| VAC/VAE | 31 (8.20) | 10.23 |
| IVAC | 20 (5.29) | 6.60 |
| PVAP | 9 (2.38) | 2.97 |
| VAP but no VAE | 9 (2.38) | 2.97 |
| VAC but no VAP | 12 (3.17) | 3.96 |
| IVAC but no VAP | 4 (1.06) | 1.32 |
| PVAP but no VAP | 2 (0.53) | 0.66 |
| Both VAC and VAP | 19 (5.02) | 6.26 |
Fig. 1Incidence rate of VAC, IVAC, PVAP and VAP from July 2018 to June 2019
Test characteristics of VACs for the diagnosis of VAP
|
|
|
|
|
| |
|---|---|---|---|---|---|
| VAC for VAP | 61.3% (42.2–78.2) | 97.4% (95.1–98.8) | 67.9% (51.1–81.0) | 96.6% (94.8–97.8) | 94.4% (91.6–96.5) |
| IVAC for VAP | 80.0% (56.3–94.3) | 96.7% (94.2–98.3) | 57.1% (42.4–70.8) | 98.9% (97.3–99.5) | 95.8% (93.2–97.6) |
| PVAP for VAP | 77.8% (40.0–97.2%) | 94.31% (91.4–96.4) | 25.0% (16.2–36.5) | 99.4% (98.1–99.8) | 93.9% (91.0–96.1) |
Antibiogram of pathogens found during VAP and IVAC surveillance in trauma ICU from July 2018 to June 2019
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
| 10 | 0 | 3 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 5 | 0 | ||
|
| 7 | 4 | 1 | 2 | 1 | 1 | 2 | 2 | 1 | 3 | 1 | |||
|
| 3 | 2 | 1 | 0 | 0 | 1 | 1 | 1 | 0 | 0 | 1 | 0 | 3 | 0 |
|
| 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | |||||
| 2 | 2 | 1 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | ||
| Methicillin resistant | 2 | 0 | ||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||
|
| 10 | 4 | 0 | 2 | 1 | 1 | ||||||||
|
| 7 | 1 | ||||||||||||
|
| 3 | 2 | ||||||||||||
|
| 2 | 2 | ||||||||||||
| 2 | ||||||||||||||
| Methicillin resistant | 2 | 2 | 2 | 1 | 1 | 0 | 0 | |||||||
AMK, amikacin; MINO, minocycline; CIPRO, ciprofloxacin; CEFOTAX, cefotaxime; IMI, imipenem; PIP, piperacillin; CEFOSULB, cefoperazone-sulbactam; CEFTAZ, ceftazidime; DOXY, doxycycline; MERO, meropenem; ERTA, ertapenem; COL, colistin; CEFEP, cefepime; TIG, tigecycline; GENT, gentamicin; CSL, cefoperazone-sulbactam TETRA, tetracycline; LEVO, levofloxacin, CHL, chloramphenicol; VANCO, vancomycin; TEICO, teicoplanin; SAM, ampicillin-sulbactam; LNZ, linezolid, CLIND, clindamycin; OXA, oxacillin; ERYTHRO, erythromycin
List of previous studies conducted to compare VAP and VAE in different study populations
|
|
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|---|
| Piriyapatsom et al.,5 Massachusetts, USA | Retrospective, single-center, trauma subjects, IVAC compared to VAP | IVAC or VAP 35.6 | IVAC 28.12 | 91.45 | 58.06 | 75.14 | IVAC criteria had a low accuracy for identifying VAP-NHSN in subjects with high-risk trauma |
| Klouwenberg et al.,6 Netherlands | Prospective cohort study in two Dutch academic medical centers | VAC 10/1000 MV days | VAC 33% | Noted much poorer concordance between the novel VAE algorithm and VAP. The incidence rate of VAC, IVAC, VAE-VAP, and VAP in the present study was comparable (10.23, 6.60, 6.26, and 9.24, respectively). Poor concordance noted between VAP and VAE in the present study too | |||
| Fan et al.,7 Wuhan, China | Meta-analysis of 18 studies | VAC 10.23 | VAE <50% | >80% | <50% | >80% | VAE surveillance missed many cases of VAP, and the population characteristics identified by the two surveillance paradigms differed |
| Boyer et al.,8 St Louis, Missouri | Prospectively surveyed 1,209 patients ventilated for 2 calendar days at medical surgical ICU | VACs 5.5% (7/1,000 MV days) | VAC 25.9% | VAC criteria captured a minority of VAP episodes | |||
| Meagher et al.,9 USA | Retrospective study, adult trauma patients (2012–2017) | VAE 8.1% | The proportions of individual entities were found to be comparable to the present study for VAC (8.2%), VAP (7.41%), and VAE + VAP (5.02%) | ||||
| Younan et al.,10 China | Retrospective study, trauma patients | “New” VAP 6.6% | The concordance between new and old definitions was poor (kappa 0.22), similar to the present study |